Kymera Therapeutics, Inc. KYMR
Kymera Therapeutics, Inc. (Nasdaq: KYMR) is an immunology/inflammation drug developer. Its lead program, KT-621, is in Phase 2 for Atopic Dermatitis and Asthma.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| KT-621 | Moderate to Severe Atopic Dermatitis (AD) | small molecule | Phase 2 |
| KT-621 | Moderate to Severe Asthma | small molecule | Phase 2 |
| KT-579 | Lupus | small molecule | Phase 1 |
| KT-485/SAR447971 | Immunology/inflammation (excluding oncology) | small molecule | Phase 1 |
| KT-200 | Undisclosed | small molecule | Pre-clinical |
Recent results and decisions
- Oct 29, 2026positive KT-579 Phase 1 healthy volunteer trial demonstrated deep sustained IRF5 degradation (≥90% median degradation), robust modulation of disease-relevant biomarkers, and favorable safety profile comparable to placebo.
The positive results from the Phase 1 healthy volunteer trial of KT-579, which we reported today, demonstrate strong translation of its preclinical pharmacology into humans and highlight its potential to modulate multiple core inflammatory pathways.
Filing - Oct 29, 2026n/a KT-579 LUMORA Phase 1b trial in approximately 30 lupus patients planned to start by early 2027.
The KT-579 LUMORA Phase 1b trial in lupus patients is planned to start by early 2027.
Filing - Oct 29, 2026completed enrollment Last patient completed last visit in KT-621 BROADEN2 Phase 2b atopic dermatitis trial, with topline data to be reported by year-end 2026.
In October 2026, the last patient received their final dose and completed the week 16 visit in the KT-621 BROADEN2 Phase 2b clinical trial in patients with moderate to severe AD.
Filing
5 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.